FDA Grants Accelerated Approval to INOVIO’s VOCERYQ for Adults With RRP
The immunotherapy is approved to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis.
The immunotherapy is approved to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis.